REdo Transcatheter Aortic VALVE Implantation
for the Management of
Transcatheter Aortic Valve Failure (REVALVE)
about tavi
Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI) is a key-hole technique to replace an aortic heart valve that is narrowed and/or leaking. Although TAVI is a safe and effective treatment for a faulty aortic heart valve, the new TAVI valve will not last forever. Because it is a ’tissue’ valve (made from the lining of a cow or pig heart), the valve will fail after a period of time as the tissue degenerates.
When the TAVI valve fails, a viable treatment option is to perform a ‘Redo TAVI’ procedure, implanting a second TAVI valve inside the first failing valve.
The REVALVE Leadership Team
Professor Dan Blackman
Chief Investigator
Consultant Interventional Cardiologist, Leeds Teaching Hospitals NHS Trust
Professor of Interventional Cardiology, University of Leeds
View profile
Professor Dan Blackman MBChB MD MRCP is Consultant Interventional Cardiologist at Leeds Teaching Hospitals NHS Trust, Professor of Interventional Cardiology at the University of Leeds, and Chairman of the British Cardiovascular Intervention Society Structural Heart Group.
Professor Blackman is one of the leading interventional cardiologists in the United Kingdom, and has an international reputation in the field of trans-catheter valve intervention, including TAVI. He has performed over 2500 TAVI procedures, has proctored TAVI worldwide, and is also active in the field of trans-catheter mitral and tricuspid valve intervention including trans-catheter edge to edge repair (TEER).
Professor Blackman is a committed innovator and clinical researcher in interventional cardiology. He is currently Chief Investigator of the multi-centre multi-national REVALVE study and UK PI of the NAVIGATE Bicuspid RCT. He has published over 180 peer-reviewed articles in the field.
Having been Honorary Secretary of the British Cardiovascular Intervention Society from 2016 to 2020, he is now Chair of the BCIS Structural Group.
Dave Pickles
Study Manager
Leeds
View profile
Dave Pickles is a registered nurse and qualified in 2001, later completing a Post Graduate Diploma in Clinical Trials from the University of Edinburgh. He is the REVALVE Study Manager, helping to drive recruitment, ensuring that it remains within budget and maintaining regulatory compliance.
In previous roles, Dave led a team of rheumatology clinical research nurses, oversaw the delivery of a complex research portfolio, ensured regulatory compliance, and handled budgeting and resource allocation. Later, as Lead Nurse in the Clinical Digital Team, Dave led major projects including the introduction of digital nursing care plans and electronic observations at a Children’s Hospital.
Dave has extensive experience managing clinical and research teams, with a focus on professional development, maintaining high standards, and promoting a supportive, respectful environment. He is also experienced in strategic planning and resource management, demonstrated through both clinical leadership roles and trustee work with the Airedale Homes Project.
Purpose of The Study
Outcomes of Redo TAVI
The main purpose of this study is to carefully evaluate patients being treated by Redo TAVI in order to document the short-term and long-term outcomes of the procedure. The study will also obtain information about which factors predict those outcomes.
How to perform Redo TAVI
The study will provide doctors the information they need to understand the best way to treat patients who present with TAVI valve failure, and in particular how to perform Redo TAVI procedures with the best possible outcomes for patients.
Surgery and medical therapy
The study will also assess outcomes in patients who present with TAVI valve failure but are not suitable for Redo TAVI, and instead are treated either by open-heart surgery and surgical aortic valve replacement, or by medical therapy (medication).
